A Phase I/II Study of E7389 Halichondrin B Analog (NSC 707389; IND 64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency

Trial Profile

A Phase I/II Study of E7389 Halichondrin B Analog (NSC 707389; IND 64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 17 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top